Search results
Showing 91 to 105 of 698 results for must
In development Reference number: GID-TA10575 Expected publication date: TBC
NICE makes 4 types of recommendation that allow us to produce clear, directive, actionable guidance that is easy to understand and put into practice.
Permission to use NICE content for artificial intelligence (AI) purposes
Permission form to use NICE content for artificial intelligence (AI) purposes.
Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA803)
Evidence-based recommendations on risankizumab (Skyrizi) for treating active psoriatic arthritis in adults.
This guideline covers prescribing of cannabis-based medicinal products for people with intractable nausea and vomiting, chronic pain, spasticity and severe treatment-resistant epilepsy.
Topotecan for the treatment of relapsed small-cell lung cancer (TA184)
Evidence-based recommendations on topotecan for treating relapsed small-cell cancer in adults.
View recommendations for TA184Show all sections
hour before any other drink, food or medicine. You must take the tablets standing or sitting up. You must not lie down for...
Healthy workplaces: improving employee mental and physical health and wellbeing (QS147)
This quality standard covers the health and wellbeing of all employees, including their mental health. It describes high-quality care in priority areas for improvement. It does not cover managing long-term sickness absence.
View quality statements for QS147Show all sections
Sections for QS147
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke in adults.
This guideline covers assessing and managing pelvic fractures, open fractures and severe ankle fractures (known as pilon fractures and intra-articular distal tibia fractures) in pre-hospital settings (including ambulance services), emergency departments and major trauma centres. It aims to reduce deaths and long-term health problems by improving the quality of emergency and urgent care.
Social care for older people with multiple long-term conditions (QS132)
This quality standard covers the planning and delivery of social care and support for older people (aged 65 and over) with multiple long-term conditions. It includes people living in their own homes, in specialist settings or in care homes, both those who receive support with funding for their social care and those who do not. It describes high-quality care in priority areas for improvement.
View quality statements for QS132Show all sections
Sections for QS132
- Quality statements
- Quality statement 1: Including physical and mental health needs in a care and support needs assessment
- Quality statement 2: Discussing services that could help at a care and support needs assessment
- Quality statement 3: Named care coordinator
- Quality statement 4: Care planning
- Quality statement 5: Review of health and social care plan
- About this quality standard
Early value assessment (EVA) guidance on digital technologies for delivering multidisciplinary weight-management services.
Transition between inpatient mental health settings and community or care home settings (NG53)
This guideline covers the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It aims to help people who use mental health services, and their families and carers, to have a better experience of transition by improving the way it’s planned and carried out.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.